The Silent Liver Function Mayhem: Unrevealing The Mystery Of Vanishing Bile Duct Syndrome
DOI:
https://doi.org/10.36283/ziun-pjmd15-1/031Keywords:
Intrahepatic, Bile Duct , Cholestasis, Adverse Drug Reactions, Bile Duct Diseases, Lymphoproliferative Diseases, Drug Induced Liver InjuryAbstract
Vanishing Bile Duct Syndrome (VBDS) is a rare form of cholestatic liver disease that is characterized by the destruction of intrahepatic biliary tree segments. For this narrative review to explore the clinical spectrum, pathophysiology, and outcomes of VBDS, a comprehensive literature search was performed using PubMed, google scholar and other academic databases from year 1995-2025. It was identified that hepatic conditions that can lead to VBDS are primary biliary cholangitis (PBC) and primary sclerosing cholangitis. Our main focus was on non-hepatic aetiologies that have been linked to VBDS such as neoplastic illnesses (especially lymphoma) or drug-induced liver damage (DILI). The diagnosis of VBDS is confirmed by ductopenia, which is a 50% decrease of the interlobular bile ducts on liver biopsy. Significant hepatic inflammation and damage were also observed in chronic active hepatitis. Management centres on withdrawal of the offending agent with added symptomatic relieve with Rifampin, Cholestyramine and ursodeoxycholic acid. High doses of ursodeoxycholic are also beneficial to relieve symptoms of pruritis and improving biochemical markers. In severe cases liver transplant is the only choice.
References
1. Ludwig J, Wiesner RH, LaRusso NF. Idiopathic adulthood ductopenia. J Hepato 1988;7(2):193–9. Doi: https://doi.org/10.1016/S0168-8278(88)80482-3
2. Desmet VJ. Vanishing bile duct syndrome in drug-induced liver disease. J Hepatol 1997;26(Suppl 1):31–5. Doi: https://doi.org/10.1016/S0168-8278(97)82330-6
3. Nakanuma Y, Tsuneyama K, Harada K. Pathology and pathogenesis of intrahepatic bile duct loss. J Hepatobiliary Pancreat Surg 2001; 8:303–15. Doi: https://doi.org/10.1007/s005340170002.
4. Reau, N. S., & Jensen, D. M. (2008). Vanishing Bile Duct Syndrome. Clinics in Liver Disease, 12(1), 203–217. Doi:10.1016/j.cld.2007.11.00
5. Levy C, Lindo KD. Drug-induced cholestasis. Clin Liver Dis 2003; 17:311– 30.
6. Chitturi S, Farrell GC. Drug-induced cholestasis. Semin Gastrointestinal Dis 2001; 12:113–24.
7. Geubel AP, Sempoux CL. Drug and toxin-induced bile duct disorders. J Gastroenterol Hepatol 2000; 15:1232–38. Doi: https://doi.org/10.1046/j.1440-1746.2000.2369.x
8. Lv T, Yu H, Han X, Wee A, Liu J, Li M, Xu J, Hu X, Li J, Duan W, Wang T. Histopathological features predicting long-term clinical outcomes in patients with vanishing bile duct syndrome. Journal of Clinical and Translational Hepatology. 2023 Apr 4;11(5):1161. Doi: 10.14218/JCTH.2022.00039
9. Sabu S, Chakrabarty G, Shahid F, Shaid F. Vanishing Bile Duct Syndrome: A Differential Diagnosis for Painless Jaundice. Cureus. 2024 Sep 5;16(9). Doi: 10.7759/cureus.68724
10. Wang NL, Chen L, Lin J, Lu Y, Fang WY, Xie XB, Wang JS. Non-invasive biomarkers for identification of vanishing bile duct syndrome among children with acute cholestatic hepatitis. Translational Pediatrics. 2023 Oct 27;12(10):1782. Doi:10.21037/tp-23-305
11. Hautekeete ML, Horsmans Y, Van Waeyenberge C, et al. HLA association of amoxicillin-clavulanate-induced hepatitis. Gastroentero 1999; 117:1181–6. Doi: https://doi.org/10.1016/S0016-5085(99)70404-X
12. Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease. Mechanisms of action and therapeutic use revisited. Hepatology 2002; 36:525–31. Doi: https://doi.org/10.1053/jhep.2002.36088
13. Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid mechanisms of action and clinical use in hepatobiliary disorders. J Hepatol 2001; 35:134–46. Doi: 10.1016/S0168-8278(01)00092-7
14. Hempfling W, Dilger K, Beuers U. Systematic review: ursodeoxycholic acid- adverse effects and drug interactions. Aliment Pharmacol Ther 2003; 18:963– 972. Doi: https://doi.org/10.1046/j.1365-2036.2003.01792.x
15. Danica J, Irena H, Davor R, Mate S, Marijana C, Boris V, Igor F. Vanishing bile duct syndrome associated with azithromycin in a 62‐year‐old man. Basic & clinical pharmacology & toxicology. 2010 Jan;106(1):62-5. Doi: https://doi.org/10.1111/j.1742-7843.2009.00474.x
16. Borgonovo E, De Cristofaro J, Aletti F, Pedica F, D'Alessio A, D'Alessio Sr A. Edoxaban-Induced Vanishing Bile Duct Syndrome: A Case Report with Review of the Literature. Cureus. 2024 Aug 28;16(8). Doi: 10.7759/cureus.68071
17. Faragalla K, Lau H, Wang HL, Liu J. Cloxacillin‐induced acute vanishing bile duct syndrome: A case study and literature review. British Journal of Clinical Pharmacology. 2022 Oct;88(10):4633-8. Doi: https://doi.org/10.1111/bcp.15445
18. Kalal C, Wagh A, Patel A, Joshi H, Surude R, Singh A, Bhatia S, Bhatt C. A disquiet find: anabolic-androgenic steroids and vanishing bile duct syndrome. In Hepatology Forum 2020 Sep 21 (Vol. 1, No. 3, p. 109). Doi: 10.14744/hf.2020.2020.0021
19. Shah P, Larson B, Wishingrad M, Nissen N, Björnsson E, Sundaram V. Now you see it, now you do not: a case of infliximab-induced vanishing bile duct syndrome. ACG Case Reports Journal. 2019 Jul 1;6(7): e00134. Doi:10.14309/crj.0000000000000134
20. Eiswerth MJ, Heckroth MA, Ismail A, Gondim DD, Kaufman R, Eiswerth M, Kaufman RM. Infliximab-induced vanishing bile duct syndrome. Cureus. 2022 Feb 5;14(2). Doi: 10.7759/cureus.21940
21. Basturk A, Artan R, Yılmaz A, Gelen MT, Duman O. Acute vanishing bile duct syndrome after the use of ibuprofen. Arab Journal of Gastroenterology. 2016 Sep 1;17(3):137-9. Doi: https://doi.org/10.1016/j.ajg.2016.08.006
22. Smith LA, Ignacio JR, Winesett MP, Kaiser GC, Lacson AG, Gilbert-Barness E, González-Peralta RP, Wilsey Jr MJ. Vanishing bile duct syndrome: amoxicillin-clavulanic acid associated intra-hepatic cholestasis responsive to ursodeoxycholic acid. Journal of pediatric gastroenterology and nutrition. 2005 Oct 1;41(4):469-73.
23. Lildar T, Muhammad O, Shah M. S1950 Vanishing Bile Duct Syndrome Due to Commonly Used Treatment for Urinary Tract Infection. Official journal of the American College of Gastroenterology 2023 Oct 1;118(10S): S1442. Doi: 10.14309/01.ajg.0000957440.81074.63
24. Piawah S, Hyland C, Umetsu SE, Esserman LJ, Rugo HS, Chien AJ. A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel. NPJ Breast Cancer. 2019 Jun 14;5(1):17. Doi: https://doi.org/10.1038/s41523-019-0112-z
25. Abugroun A, Garcia IC, Ahmed F, Potts S, Flicker M. The first report of atovaquone/proguanil-induced vanishing bile duct syndrome: case report and mini-review. Travel Medicine and Infectious Disease. 2019 Nov 1; 32:101439. Doi: https://doi.org/10.1016/j.tmaid.2019.06.010
26. Bessone F, Hernández N, Tanno M, Roma MG. Drug-induced vanishing bile duct syndrome: from pathogenesis to diagnosis and therapeutics. In Seminars in Liver Disease 2021 Aug; 41 (03) :331-348. Thieme Medical Publishers, Inc. Doi: 10.1055/s-0041-1729972
27. Lin WC, Hsieh TS, Chu CY. Case report: Development of vanishing bile duct syndrome in Stevens-Johnson syndrome complicated by hemophagocytic lymphohistiocytosis. Frontiers in Medicine. 2022 Oct 24;9: 975754. Doi: https://doi.org/10.3389/fmed.2022.975754
28. Musleh M, Shahid M, Almadhoun K, Singla S. S3346 Vanishing Bile Duct in a Patient with Bipolar Disorder. Official journal of the American College of Gastroenterology| ACG. 2020 Oct 1;115: S1741. Doi: 10.14309/01.ajg.0000715432. 05720.b9
29. Patodiya B, Ramani VK, Rao PN, Sharma M, Patodiya S, Reddy DN. A rare presentation of vanishing bile duct syndrome in Hodgkin lymphoma: Case report. SAGE Open Medical Case Reports. 2023 Nov; 11:2050313X231208968. Doi: https://doi.org/10.1177/2050313X231208968
30. Singh PK, Rattan R, Kumar R, Yadav BS. Severe Jaundice, due to Vanishing Bile Duct Syndrome in Hodgkin’s Lymphoma, Fully Reversible after Chemotherapy. Practice. 2023; 2:15-7. Doi: 10.56831/PSSRP-02-062
31. Ballonoff A, Kavanagh B, Nash R, Drabkin H, Trotter J, Costa L, Rabinovitch R. Hodgkin lymphoma-related vanishing bile duct syndrome and idiopathic cholestasis: statistical analysis of all published cases and literature review. Acta Oncologica. 2008 Jan 1;47(5):962-70. Doi: https://doi.org/10.1080/02841860701644078
32. Greca RD, Cunha-Silva M, Costa LB, Costa JG, Mazo DF, Sevá-Pereira T, Nascimento MM, Pereira IE, Oliveira FC, Faria GA, Neto FL. Vanishing bile duct syndrome related to DILI and Hodgkin lymphoma overlap: A rare and severe case. Annals of hepatology. 2020 Jan 1;19(1):107-12. Doi: https://doi.org/10.1016/j.aohep.2019.06.010
33. Keim L, Cormier I. Vanishing Bile Duct Syndrome: A Paraneoplastic Phenomenon Secondary to Occult Hodgkin's Lymphoma. Graduate Medical Education Research Journal. 2020 Sep;2(1):61. Doi: https://doi.org/10.32873/unmc.dc.gmerj.2.1.061
34. Parkhi M, Premkumar M, Bal A, Das A, Jain S, Mitra S. Acute liver failure caused by lymphocyte-depleted Hodgkin lymphoma in tuberculosis and HIV infected patient. Autopsy and Case Reports. 2024 May 20;14: e2024490. Doi: https://doi.org/10.4322/acr.2024.490
35. Velangini SP, Boddu D, Balakumar S, Premanand A, Kishore R, Mathew LG. Vanishing bile duct syndrome secondary to Hodgkin lymphoma in a child. Journal of Pediatric Hematology/Oncology. 2022 Aug 1;44(6): e945-7. Doi: 10.1097/MPH.0000000000002505
36. Ma S, Cai D, Miao Y, Deng B, Yan X, Gao R. Case Report: Vanishing bile duct syndrome in Hodgkin's lymphoma: a case highlighting jaundice and lymphadenopathy as early clues. Front Immunol. 2025 May 21; 16:1561110. Doi: 10.3389/fimmu.2025.1561110.
37. Nano O, Ivanov S, Kapoor T. Vanishing bile duct syndrome in a patient with recurrent Hodgkin lymphoma. Journal of Medical Cases. 2023 May 31;14(5):162. Doi: 10.14740/jmc4073
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Pakistan Journal of Medicine and Dentistry
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access article distributed under the terms of the CreativeCommons Attribution License (CC BY) 4.0 https://creativecommons.org/licenses/by/4.0/
Metrics
How to Cite
